| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/24/2014 | EP2780454A2 Modified rnai agents |
| 09/24/2014 | EP2780353A1 Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| 09/24/2014 | EP2780352A1 Mannosylated compounds useful for the prevention and the treatment of infectious diseases |
| 09/24/2014 | EP2780348A1 Process for the preparation of tenofovir |
| 09/24/2014 | EP2780344A1 Thieno [2, 3 - c]pyrazoles for use as potassium channel inhibitors |
| 09/24/2014 | EP2780343A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors |
| 09/24/2014 | EP2780342A1 Aminoquinazoline derivatives and their salts and methods of use |
| 09/24/2014 | EP2780341A1 Kinase modulating compounds, compositions containing the same and use thereof |
| 09/24/2014 | EP2780338A1 Uracil derivatives as axl and c-met kinase inhibitors |
| 09/24/2014 | EP2780336A1 Structural variants of mycolactones for use in modulating inflammation, immunity and pain |
| 09/24/2014 | EP2780332A1 Morpholinyl benzotriazine for use in cancer therapy |
| 09/24/2014 | EP2780331A1 Pharmaceutically active pyrazine derivatives |
| 09/24/2014 | EP2780330A1 1-pyridazinyl-hydroxyimino- 3- phenyl- propanes as gpbar1 agonists |
| 09/24/2014 | EP2780328A1 N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 09/24/2014 | EP2780327A1 Polymorphic forms of ivabradine hydrochloride |
| 09/24/2014 | EP2780326A1 Method for inhibition of deubiquitinating activity |
| 09/24/2014 | EP2780324A1 Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
| 09/24/2014 | EP2780322A1 Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
| 09/24/2014 | EP2780321A1 Mono-fluoro beta-secretase inhibitors |
| 09/24/2014 | EP2780317A2 The novel reference markers for fesoterodine fumarate |
| 09/24/2014 | EP2780316A1 Esters of dcpla and methods of treatment using the same |
| 09/24/2014 | EP2780032A1 Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| 09/24/2014 | EP2780031A1 Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| 09/24/2014 | EP2780029A1 Oral leptin formulations and uses thereof |
| 09/24/2014 | EP2780018A1 Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| 09/24/2014 | EP2780017A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
| 09/24/2014 | EP2780016A1 An extended release formulation of a direct thrombin inhibitor |
| 09/24/2014 | EP2780015A1 Muscarinic m1 receptor agonists |
| 09/24/2014 | EP2780014A1 Modulators of methyl modifying enzymes, compositions and uses thereof |
| 09/24/2014 | EP2780013A1 Modulators of methyl modifying enzymes, compositions and uses thereof |
| 09/24/2014 | EP2780012A1 Methods of treatment with deferiprone |
| 09/24/2014 | EP2780011A1 Combination therapy for ovarian cancer |
| 09/24/2014 | EP2780010A1 Combination therapy of hsp90 inhibitors with braf inhibitors |
| 09/24/2014 | EP2780009A1 Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |
| 09/24/2014 | EP2780008A1 Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof |
| 09/24/2014 | EP2780007A1 Apricitabine and pi combination therapy |
| 09/24/2014 | EP2780006A1 Composition for transdermal administration of rivastigmine |
| 09/24/2014 | EP2780005A1 Controlled release of active using ph |
| 09/24/2014 | EP2780004A1 Film-forming formulation |
| 09/24/2014 | EP2780003A1 Treatment of adrenal insufficiency |
| 09/24/2014 | EP2780002A1 Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability |
| 09/24/2014 | EP2780000A1 Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| 09/24/2014 | EP2779999A2 Pharmaceutical formulations comprising atorvastatin and glimepiride |
| 09/24/2014 | EP2779998A1 Polymeric colorant compositions and methods of use |
| 09/24/2014 | EP2779997A1 Liquid-filled hard gel capsule pharmaceutical formulations |
| 09/24/2014 | EP2779956A1 Stent |
| 09/24/2014 | EP2779842A1 Composition for protection against cell-damaging effects |
| 09/24/2014 | EP2779839A1 Products for oral administration comprising extracts of punica granatum (pomegranate), intended for a pet, and applications of same |
| 09/23/2014 | US8842266 Pharmaceutical mixture evaluation |
| 09/23/2014 | US8841464 Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives |
| 09/23/2014 | US8841463 Cathepsin C inhibitors |
| 09/23/2014 | US8841462 Bicyclic heterocycles as MEK kinase inhibitors |
| 09/23/2014 | US8841457 Process for cyclooxygenase-2 selective inhibitor |
| 09/23/2014 | US8841453 Hybrid cholinesterase inhibitors |
| 09/23/2014 | US8841450 Compounds useful as inhibitors of ATR kinase |
| 09/23/2014 | US8841449 Compounds useful as inhibitors of ATR kinase |
| 09/23/2014 | US8841447 Process for the preparation of alogliptin |
| 09/23/2014 | US8841446 Medicaments containing vardenafil hydrochloride trihydrate |
| 09/23/2014 | US8841431 Hepcidin binding nucleic acids |
| 09/23/2014 | US8841427 Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and applications thereof |
| 09/23/2014 | US8841351 Polymeric topical compositions |
| 09/23/2014 | US8841350 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| 09/23/2014 | US8841349 Stabilize compositions based on monoalkyl glycerol ethers and aromatic alcohols |
| 09/23/2014 | US8841348 Anti-inflammatory formulation |
| 09/23/2014 | US8841347 Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use |
| 09/23/2014 | US8841346 Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| 09/23/2014 | US8841345 Compositions and methods for treatment of premature ejaculation |
| 09/23/2014 | US8841344 Method of using omega-3 fatty acids |
| 09/23/2014 | US8841342 Carrier |
| 09/23/2014 | US8841341 Pharmaceutical composition effective against biofilms |
| 09/23/2014 | US8841340 Solid forms of an antiviral compound |
| 09/23/2014 | US8841339 Synergistic antifouling compositions comprising 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile |
| 09/23/2014 | US8841338 Synergistic antifouling compositions comprising 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile |
| 09/23/2014 | US8841337 Compounds useful as inhibitors of ATR kinase |
| 09/23/2014 | US8841336 Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| 09/23/2014 | US8841335 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration |
| 09/23/2014 | US8841334 Compounds as cannabinoid receptor ligands and uses thereof |
| 09/23/2014 | US8841333 Methods for treating nephrolithiasis |
| 09/23/2014 | US8841332 Fungicidal N-(2-phenoxyethyl)carboxamide derivatives and their aza, thia and sila analogues |
| 09/23/2014 | US8841331 Inhibitors of human immunodeficiency virus replication |
| 09/23/2014 | US8841330 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| 09/23/2014 | US8841329 Nicotinic attenuation of CNS inflammation and autoimmunity |
| 09/23/2014 | US8841327 Heterocycles substituted pyridine derivatives and antifungal agent containing thereof |
| 09/23/2014 | US8841326 Therapeutic curcumin derivatives |
| 09/23/2014 | US8841325 Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells |
| 09/23/2014 | US8841324 Heterocyclic compounds as autotaxin inhibitors |
| 09/23/2014 | US8841323 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
| 09/23/2014 | US8841322 Method for increasing the activity of lysosomal enzymes |
| 09/23/2014 | US8841321 Quinoline derivatives as antibacterial agents |
| 09/23/2014 | US8841320 Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging |
| 09/23/2014 | US8841319 Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| 09/23/2014 | US8841318 Substituted heterocycles as janus kinase inhibitors |
| 09/23/2014 | US8841317 Noscapine and analogs and methods related thereto |
| 09/23/2014 | US8841316 Multicomponent crystalline system of rosuvastatin calcium salt and vanillin |
| 09/23/2014 | US8841315 Inhibitors of protein kinases |
| 09/23/2014 | US8841314 2-Thiopyrimidinones |
| 09/23/2014 | US8841313 CCR2 antagonists and uses thereof |
| 09/23/2014 | US8841312 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| 09/23/2014 | US8841311 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments |
| 09/23/2014 | US8841310 Combinations of a pyrimidine containing NNRTI with RT inhibitors |